Intravenous immune globulin suppresses angiogenesis in mice and humans

Reo Yasuma, Valeria Cicatiello, Takeshi Mizutani, Laura Tudisco, Younghee Kim, Valeria Tarallo, Sasha Bogdanovich, Yoshio Hirano, Nagaraj Kerur, Shengjian Li, Tetsuhiro Yasuma, Benjamin J. Fowler, Charles B. Wright, Ivana Apicella, Adelaide Greco, Arturo Brunetti, Balamurali K. Ambati, Sevim Barbasso Helmers, Ingrid E. Lundberg, Ondrej ViklickyJeanette H.W. Leusen, J. Sjef Verbeek, Bradley D. Gelfand, Ana Bastos-Carvalho, Sandro De Falco, Jayakrishna Ambati

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

Human intravenous immune globulin (IVIg), a purified IgG fraction composed of ~ 60% IgG1 and obtained from the pooled plasma of thousands of donors, is clinically used for a wide range of diseases. The biological actions of IVIg are incompletely understood and have been attributed both to the polyclonal antibodies therein and also to their IgG (IgG) Fc regions. Recently, we demonstrated that multiple therapeutic human IgG1 antibodies suppress angiogenesis in a target-independent manner via FcγRI, a high-affinity receptor for IgG1. Here we show that IVIg possesses similar anti-angiogenic activity and inhibited blood vessel growth in five different mouse models of prevalent human diseases, namely, neovascular age-related macular degeneration, corneal neovascularization, colorectal cancer, fibrosarcoma and peripheral arterial ischemic disease. Angioinhibition was mediated by the Fc region of IVIg, required FcγRI and had similar potency in transgenic mice expressing human FcγRs. Finally, IVIg therapy administered to humans for the treatment of inflammatory or autoimmune diseases reduced kidney and muscle blood vessel densities. These data place IVIg, an agent approved by the US Food and Drug Administration, as a novel angioinhibitory drug in doses that are currently administered in the clinical setting. In addition, they raise the possibility of an unintended effect of IVIg on blood vessels.

Original languageEnglish
Article number15002
JournalSignal Transduction and Targeted Therapy
Volume1
DOIs
StatePublished - 2016

Bibliographical note

Publisher Copyright:
© 2016 West China Hospital, Sichuan University.

Funding

We thank TS Khurana, S Bondada, K Ambati, AM Rao and GS Rao for discussions; L Toll, GR Pattison R King, L Xu, M McConnell, C Payne, D Robertson, G Botzet, A Uiettenbogaard, E Lindroos and the Institute of Genetics and Biophysics animal house and integrated microscopy facilities for technical assistance. JA was supported by US National Institutes of Health (NIH) grants DP1GM114862, R01EY018350, R01EY018836, R01EY020672, R01EY022238 and R01EY024068, Doris Duke Distinguished Clinical Scientist Award, Burroughs Wellcome Fund Clinical Scientist Award in Translational Research, Ellison Medical Foundation Senior Scholar in Aging Award, Foundation Fighting Blindness Individual Investigator Research Award, Harrington Discovery Institute Scholar-Innovator Award, Carl Marshall Reeves Foundation, John Templeton Foundation, Dr E Vernon Smith and Eloise C Smith Macular Degeneration Endowed Chair, and Research to Prevent Blindness departmental unrestricted grant; SDeF by AIRC (Associazione Italiana Ricerca sul Cancro) grant IG11420 and Italian Ministry for Scientific Research, project PON01_01434; BJF and SB by NIH T32HL091812 and UL1RR033173; YH by Alcon Research Award; AB-C by the Programme for Advanced Medical Education (sponsored by Fundação Calouste Gulbenkian, Fundação Champalimaud, Ministério da Saúde and Fundação para a Ciência e Tecnologia, Portugal) and Bayer Global Ophthalmology Research Award; YH by Alcon Japan Research award; NK by Beckman Initiative for Macular Research and NIH K99/R00EY024336; CBW by International Retinal Research Foundation; BDG by American Heart Association and International Retinal Research Foundation; BKA by NIH R01EY017182 and R01EY017950, VA Merit Award and Department of Defense; and OV by Ministry of Health, Czech Republic—conceptual development of research organization (Institute for Clinical and Experimental Medicine—IKEM, IN 00023001). JA is a co-founder of iVeena Holdings, iVeena Pharmaceuticals, iVeena Delivery Systems and Inflammasome Therapeutics, and has received honoraria from Allergan and research funding from Olix Pharmaceuticals unrelated to this work. JA and SDeF are named as inventors on patent applications filed by the University of Kentucky relating to the technology described in this work.

FundersFunder number
Alcon Japan Research
Harrington Discovery Institute
IKEMIN 00023001
Institute for Clinical and Experimental Medicine
Italian Ministry for Scientific ResearchPON01_01434
OliX Pharmaceuticals, Inc.
National Institutes of Health (NIH)R01EY020672, R01EY022238, T32HL091812, UL1RR033173, R01EY017950, K99/R00EY024336, R01EY018836, R01EY024068, DP1GM114862, R01EY017182, R01EY018350
U.S. Department of Defense
Burroughs Wellcome Fund
Ellison Medical Foundation
John Templeton Foundation
American the American Heart Association
International Retinal Research Foundation
Research to Prevent Blindness
Allergan Incorporated
Arnold and Mabel Beckman Initiative for Macular Research
Fundo Regional para a Ciência e Tecnologia
Carl Marshall and Mildred Almen Reeves Foundation
Foundation Fighting Blindness
Japan Society for the Promotion of Science15K10875
Ministerstvo Zdravotnictví Ceské Republiky
Associazione Italiana per la Ricerca sul CancroIG11420
Fundação Calouste Gulbenkian
Ministério da Saúde do Brasil
Fundação Champalimaud

    ASJC Scopus subject areas

    • Genetics
    • Cancer Research

    Fingerprint

    Dive into the research topics of 'Intravenous immune globulin suppresses angiogenesis in mice and humans'. Together they form a unique fingerprint.

    Cite this